Flavonoids acting on DNA topoisomerases: Recent advances and future perspectives in cancer therapy

Current Medicinal Chemistry

Volumn 19, Issue 31, 2012, Pages 5287-5293

  Russo, P ^a   Del Bufalo, A ^a,b   Cesario, A ^a,b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cell death; Clinical trials; DNA topoisomerases; DNA topoisomerases poisoning; Drug discovery and development; Flavonoids; Phenoxodiol; Systems Biology

Indexed keywords

ANTINEOPLASTIC AGENT; APIGENIN; BAICALEIN; CAMPTOTHECIN; CHRYSIN; CISPLATIN; DAIDZEIN; DNA TOPOISOMERASE; DOCETAXEL; FISETIN; FLAVONOID; GELATINASE A; GEMCITABINE; GENISTEIN; IDRONOXIL; ISOLIQUIRITIGENIN; KAEMPFEROL; LUTEOLIN; MORIN; MYRICETIN; NV 196; PACLITAXEL; QUERCETIN; RUTOSIDE; SILIBININ; TAXANE DERIVATIVE; TRIPHENDIOL; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BILE DUCT CARCINOMA; BROCCOLI; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER SURVIVAL; CANCER THERAPY; CELL CYCLE ARREST; CHEMOPROPHYLAXIS; GENOMIC INSTABILITY; GLYCYRRHIZA; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LUPIN; MELANOMA CELL; NONHUMAN; OVARY CANCER; PANCREAS CARCINOMA; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; REVIEW; SCUTELLARIA BAICALENSIS; SHALLOT; SILYBUM MARIANUM; TEA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DNA TOPOISOMERASES; FLAVONOIDS; HUMANS; ISOFLAVONES; NEOPLASMS;

EID: 84870451613     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803833272     Document Type: Review

References (81)

1. Groenman-van Waateringe, W. The Iceman's last days - the testimony of Ostrya carpinifolia. Antiquity, 2011, 85, 434-440.
2. Moerman, D.E. Native american ethnobotany. 1st ed.; Timber Press: Portland, 1998.
3. DNP. http://dnp.chemnetbase.com/dictionary-search (Accessed February 12, 2012].
4. Vaishnav, P.; Demain, A.L. Unexpected applications of secondary metabolites. Biotechnol Adv, 2011, 29, 223-229.
5. Wall, M.E.; Wani, M.C. Camptothecin and taxol: discovery to clinic-thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res, 1995, 55, 753-760.
6. Cragg, G.M.; Kingston, D.G.I.; Newman, D.J. Anticancer Agents from Natural Sources. CRC Press/Taylor & Francis: Boca Raton, 2005.
7. Butler, M.S. In: Natural Product Chemistry for Drug Discovery, RSC Biomolecular Sciences Publication No. 18; Buss, A.D.; Butler, M.S., Eds.; Royal Society of Chemistry: London, UK, 2010; pp 321-354.
8. Asensi, M.; Ortega, A.; Mena, S.; Feddi, F.; Estrela, J.M. Natural polyphenols in cancer therapy. Crit Rev Clin Lab Sci., 2011, 48, 197-216.
9. Di Carlo, G.; Mascolo, N.; Izzo, A.A., Capasso, F. Flavonoids: old and new aspects of a class of natural therapeutic drugs. Life Sci., 1999; 65, 337-353.
10. Cuyckens, F.; Claeys, M. Mass spectrometry in the structural analysis of flavonoids. J Mass Spectrom., 2004, 39, 1-15.
11. Taylor, L.P.; Grotewold; E. Flavonoids as developmental regulators. Curr Opin Plant Biol., 2005, 8, 317-323.
12. Weng, C.J.; Yen, G.C. Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo anti-metastatic activities. Cancer Metastasis Rev., 2012, Feb 8. [Epub ahead of print].
13. Liu, H.L.; Jiang, W.B.; Xie, M.X. Flavonoids: recent advances as anticancer drugs. Recent Pat Anticancer Drug Discov., 2010, 5, 152-164.
14. Prasad, S.; Phromnoi, K.; Yadav, V.R.; Chaturvedi, M.M.; Aggarwal, B.B. Targeting inflammatory pathways by flavonoids for prevention and treatment of cancer. Planta Med., 2010, 76, 1044-1063.
15. Link, A.; Balaguer, F.; Goel, A. Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Curr Med Chem., 2010, 17, 1756-1768.
16. Gilbert, E.R.; Liu, D. Flavonoids influence epigenetic-modifying enzyme activity: structure - function relationships and the therapeutic potential for cancer. Biochem Pharmacol., 2010, 80, 1771-1792.
17. Singh, B.N.; Shankar, S.; Srivastava, R.K. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol., 2011, 82, 1807-1821.
18. Tu, S.H.; Ku, C.Y.; Ho, C.T.; Chen, C.S.; Huang, C.S.; Lee, C.H.; Chen, L.C.; Pan, M.H.; Chang, H.W.; Chang, C.H.; Chang, Y.J.; Wei, P.L.; Wu, C.H.; Ho, Y.S. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits nicotine-and estrogen-induced α9-nicotinic acetylcholine receptor upregulation in human breast cancer cells. Mol Nutr Food Res., 2011, 55, 455-466.
19. Pommier, Y.; Leo, E.; Zhang, H.; Marchand, C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol., 2010, 17, 421-433.
20. Vos, S.M.; Tretter, E.M.; Schmidt, B.H.; Berger, J.M. All tangled up: how cells direct, manage and exploit topoisomerase function. Nat Rev Mol Cell Biol., 2011, 12, 827-841.
21. Heisig, P. Type II topoisomerases-inhibitors, repair mechanisms and mutations. Mutagen., 2009, 24, 465-469.
22. Noviello, E.; Aluigi, M.G.; Cimoli, G.; Rovini, E.; Mazzoni, A.; Parodi, S.; De Sessa, F.; Russo, P. Sister-chromatid exchanges, chromosomal aberrations and cytotoxicity produced by topoisomerase II-targeted drugs in sensitive (A2780) and resistant (A2780-DX3) human ovarian cancer cells: correlations with the formation of DNA double-strand breaks. Mutat Res., 1994, 311, 21-29.
23. Li, Y.; Fang, H.; Xu, W. Recent advance in the research of flavonoids as anticancer agents. Mini Rev Med Chem., 2007, 7, 663-678.
24. Ferguson, L.R. Role of plant polyphenols in genomic stability. Mutat Res., 2001, 475, 89-111.
25. Bensasson, R.V.; Zoete, V.; Jossang, A.; Bodo, B.; Arimondo, P.B.; Land, E.J. Potency of inhibition of human DNA topoisomerase I by flavones assessed through physicochemical parameters. Free Radic Biol Med., 2011, 51, 1406-1410.
26. Strick, R.; Strissel, PL.; Borgers, S.; Smith, SL.; Rowley, J.D. Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proc Natl Acad Sci U S A., 2000, 97, 4790-4795.
27. López-Lázaro, M.; Willmore, E.; Austin, C.A. The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells. Mutat Res., 2010, 696, 41-47.
28. Webb, M.R.; Ebeler, S.E.Comparative analysis of topoisomerase IB inhibition and DNA intercalation by flavonoids and similar compounds: structural determinates of activity. Biochem J., 2004, 384, 527-541.
29. Olaharski, A.J.; Mondrala, S.T.; Eastmond, D.A. Chromosomal malsegregation and micronucleus induction in vitro by the DNA topoisomerase II inhibitor fisetin. Mutat Res., 2005, 582, 79-86.
30. Cantero, G.; Campanella, C.; Mateos, S.; Cortés, F. Topoisomerase II inhibition and high yield of endoreduplication induced by the flavonoids luteolin and quercetin. Mutagen., 2006, 21, 321-325.
31. Azarova, A.M.; Lin, R.K.; Tsai, Y.C.; Liu, L.F.; Lin, C.P.; Lyu, Y.L. Genistein induces topoisomerase IIbeta- and proteasome-mediated DNA sequence rearrangements: Implications in infant leukemia. Biochem Biophys Res Commun., 2010, 399, 66-71.
32. Ye, R.; Bodero, A.; Zhou, B.B.; Khanna, K.K.; Lavin, M.F.; Lees-Miller, S.P. The plant isoflavenoid genistein activates p53 and Chk2 in an ATMdependent manner. J Biol Chem., 2001, 276, 4828-4833.
33. Park, I.; Park, K.K.; Park, J.H.; Chung, W.Y. Isoliquiritigenin induces G2 and M phase arrest by inducing DNA damage and by inhibiting the metaphase/ anaphase transition. Cancer Lett., 2009, 277, 174-181.
34. Li-Weber, M. New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat Rev., 2009, 35, 57-68.
35. Rho, Y.H.; Lee, B.W.; Park, K.H.; Bae, Y.S. Cudraflavanone A purified from Cudrania tricuspidata induces apoptotic cell death of human leukemia U937 cells, at least in part, through the inhibition of DNA topoisomerase I and protein kinase C activity. Anticancer Drugs., 2007, 18, 1023-1028.
36. Chowdhury, A.R.; Sharma, S.; Mandal, S.; Goswami, A.; Mukhopadhyay, S.; Majumder, H.K. Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem J., 2002, 366(, 653-661.
37. Davis-Searles, P.R.; Nakanishi, Y.; Kim, N.C.; Graf, T.N.; Oberlies, N.H.; Wani, M.C.; Wall, M.E.; Agarwal, R.; Kroll, D.J. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res., 2005, 65, 4448-5714.
38. López-Lázaro, M.; Calderón-Montaño, J.M.; Burgos-Morón, E.;, Austin, C.A. Green tea constituents (-)-epigallocatechin-3-gallate (EGCG) and gallic acid induce topoisomerase I- and topoisomerase II-DNA complexes in cells mediated by pyrogallol-induced hydrogen peroxide. Mutagen., 2011, 26, 489-498.
39. Patra, S.K.; Rizzi, F.; Silva, A.; Rugina, D.O.; Bettuzzi, S. Molecular targets of (-)-epigallocatechin-3-gallate (EGCG): specificity and interaction with membrane lipid rafts. J Physiol Pharmacol., 2008, 59 (Suppl 9), 217-235.
40. Neukam, K.; Pastor, N.; Cortés, F. Tea flavanols inhibit cell growth and DNA topoisomerase II activity and induce endoreduplication in cultured Chinese hamster cells. Mutat Res., 2008, 654, 8-12.
41. Berger, S.J.; Gupta, S.; Belfi, C.A.; Gosky, D.M.; Mukhtar, H. Green tea constituent (-)-epigallocatechin-3-gallate inhibits topoisomerase I activity in human colon carcinoma cells. Biochem Biophys Res Commun., 2001, 288, 101-105.
42. Suzuki, K.; Yahara, S.; Hashimoto, F.; Uyeda, M. Inhibitory activities of (-)-epigallocatechin-3-O-gallate against topoisomerases I and II. Biol Pharm Bull., 2001, 24, 1088-1090.
43. Hwang, Y.; Rhodes, D.; Bushman, F. Rapid microtiter assays for poxvirus topoisomerase, mammalian type IB topoisomerase and HIV-1 integrase: application to inhibitor isolation. Nucleic Acids Res., 2000, 28, 4884-4892.
44. Chan, L.P.; Chou, T.H.; Ding, H.Y.; Chen, P.R.; Chiang, F.Y.; Kuo, P.L.; Liang, C.H. Apigenin induces apoptosis via tumor necrosis factor receptorand Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin. Biochim Biophys Acta., 2012, 1820, 1081-1091.
45. Seo, H.S.; Choi, H.S.; Kim, S.R.; Choi, Y.K.; Woo, S.M.; Shin, I.; Woo, J.K.; Park, S.Y.; Shin, Y.C.; Ko, S.K. Apigenin induces apoptosis via extrinsic pathway, inducing p53 and inhibiting STAT3 and NFκB signaling in HER2-overexpressing breast cancer cells. Mol Cell Biochem., 2012, 366, 319-334.
46. Chao, J.I.; Su.; W.C.; Liu, H.F. Baicalein induces cancer cell death and proliferation retardation by the inhibition of CDC2 kinase and survivin associated with opposite role of p38 mitogen-activated protein kinase and AKT. Mol Cancer Ther., 2007, 6, 3039-4308.
47. Zhang, T.; Du, J.; Liu, L.; Chen, X.; Yang, F.; Jin, Q. Inhibitory effects and underlying mechanism of 7-hydroxyflavone phosphate ester in HeLa cells. PLoS One., 2012, 7, e36652.
48. Murtaza, I., Adhami, V.M.; Hafeez, B.B.; Saleem, M.; Mukhtar, H. Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappaB. Int J Cancer., 2009, 125, 2465-2473.
49. Rao, P.S.; Satelli, A.; Moridani, M.; Jenkins, M.; Rao, U.S. Luteolin induces apoptosis in multidrug resistant cancer cells without affecting the drug transporter function: involvement of cell line-specific apoptotic mechanisms. Int J Cancer., 2012, 130, 2703-2714.
50. Russo, M.; Spagnolo, C.; Tedesco, I.; Bigotto, S.; Russo, G.L. The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochem Pharmacol., 2012, 83, :6-15.
51. Weng, C.J.; Yen, G.C. Chemopreventive effects of dietary phytochemicals against cancer invasion and metastasis: phenolic acids, monophenol, polyphenol, and their derivatives. Cancer Treat Rev., 2012, 38, 76-87.
52. Kang, N.J.; Shin, S.H.; Lee, H.J.; Lee, K.W. Polyphenols as small molecular inhibitors of signaling cascades in carcinogenesis. Pharmacol Ther., 2011, 130; 310-324.
53. Jagtap, S.; Meganathan, K.; Wagh, V.; Winkler, J.; Hescheler, J.; Sachinidis, A.Chemoprotective mechanism of the natural compounds, epigallocatechin-3-O-gallate, quercetin and curcumin against cancer and cardiovascular diseases. Curr Med Chem., 2009, 16, 1451-1462.
54. Constantinou, A.I.; Husband, A. Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4- hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex. Anticancer Res., 2002, 22, 2581-2585.
55. Kamsteeg, M.; Rutherford, T.; Sapi, E.; Hanczaruk, B.; Shahabi, S.; Flick, M.; Brown, D.; Mor, G. Phenoxodiol-an isoflavone analog-induces apoptosis in chemoresistant ovarian cancer cells. Oncogene., 2003, 22, 2611-2620.
56. Sapi, E.; Alvero, A.B.; Chen, W.; O'Malley, D.; Hao, X.Y.; Dwipoyono, B.; Garg, M.; Kamsteeg, M.; Rutherford, T.; Mor, G. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncol Res., 2004, 14, 567-578.
57. Alvero, A.B.; O'Malley, D.; Brown, D.; Kelly, G.; Garg, M.; Chen, W.; Rutherford, T.; Mor, G. Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer., 2006, 106, 599-608.
58. Aguero, M.F.; Facchinetti, M.M.; Sheleg, Z.; Senderowicz, A.M. Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclindependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1. Cancer Res., 2005, 65, 3364-3373.
59. Yu, F.; Watts, R.N.; Zhang, X.D.; Borrow, J.M.; Hersey, P. Involvement of BH3-only proapoptotic proteins in mitochondrial-dependent Phenoxodiolinduced apoptosis of human melanoma cells. Anticancer Drugs., 2006, 17, 1151-1161.
60. Gamble, J.R.; Xia, P.; Hahn, C.N.; Drew, J.J.; Drogemuller, C.J.; Brown, D.; Vadas, M.A. Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects. Int J Cancer., 2006, 118, 2412-2420.
61. Drugs retained in pipeline list New Drug Pipeline Monitor - July 2011 http://www.pmprb-cepmb.gc.ca/english/View.asp?x=1533&mp=124 (Accessed February 12, 2012).
62. Choueiri, T.K.; Mekhail, T.; Hutson, T.E.; Ganapathi, R.; Kelly, G.E.; Bukowski, RM. Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. Ann Oncol., 2006, 17, 860-865.
63. de Souza, P.L.; Liauw, W.; Links, M.; Pirabhahar, S.; Kelly, G.; Howes, L.G. Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol), a novel isoflav-3-ene, in patients with advanced cancer. Cancer Chemother Pharmacol., 2006, 58, 427-433.
64. Howes, J.B.; de Souza, P.L.; West, L.; Huang, L.J.; Howes, L.G. Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer. BMC Clin Pharmacol., 2011, 11, 1-8.
65. Kelly, M.G.; Mor, G.; Husband, A.; O'Malley, D.M.; Baker, L.; Azodi, M.; Schwartz, P.E.; Rutherford, T.J. Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/ taxanerefractory/ resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers. Int J Gynecol Cancer., 2011, 21, 633-639.
66. Marshall Edwards, Inc. (NASDAQ: MSHL) http://www.marshalledwardsinc.com/ news/2010/06/01/marshall-edwardsannounces-final-results-halted-phase-3-clinical- trial-phenoxodiol (Accessed March 2, 2012).
67. McPherson, R.A.; Galettis, P.T.; de Souza, PL. Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells. Br J Cancer., 2009, 100, 649-655.
68. Aguero, M.F.; Venero, M.; Brown, D.M.; Smulson, M.E.; Espinoza, L.A. Phenoxodiol inhibits growth of metastatic prostate cancer cells. Prostate., 2010, 70, 1211-1221.
69. Mahoney, S.; Arfuso, F.; Rogers, P.; Hisheh, S.; Brown, D.; Millward, M.; Dharmarajan, A. Cytotoxic effects of the novel isoflavone, phenoxodiol, on prostate cancer cell lines. J Biosci., 2012, 37, 73-84.
70. Alvero, A.B.; Kelly, M.; Rossi, P.; Leiser, A.; Brown, D.; Rutherford, T.; Mor, G. Anti-tumor activity of phenoxodiol: from bench to clinic. Future Oncol., 2008, 4, 475-482.
71. http://www.marshalledwardsinc.com/our-programs/clinical-trials-0 (Accessed March 2, 2012).
72. Gibney, G.; Elfiky, A.; Bussom, S.; Hoimes, C.J.; Burns, A.; McDonough, J.A.; Rowen, E.; Cheng, Y.C.; Kelly, W.K. A phase II study of oral phenoxodiol in castrate and noncastrate prostate cancer patients with associated cytokine changes. J Clin Oncol., 2010, 28, 15s (abstr 4661).
73. Patented Medicine Prices Review Board www.pmprb-cepmb.gc.ca].
74. Mainwaring, P.N.; West, L.; Husband, A.J. Phase 1a safety and pharmacokinetic study of oral NV-196 in patients with solid tumours. J Clin Oncol., 2008, 26, 15S, (abstract 14615).
75. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) January 2006 Procedural Revision 2 http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM079736.pdf (Accessed March 8, 2012).
76. Adams, C.P.; Brantner, V.V. Spending on new drug development. Health Econ., 2010, 19, 130-141.
77. Light, D.W.; Warburton, R. Drug R&D Costs Questioned. Widely Quoted Average Cost to Bring Drugs to Market Doesn't Appear to Hold Up to Scrutiny. Genetic Engineering & Biotechnology News., 2011, 31.
78. Arrell, D.K.; Terzic, A. Network systems biology for drug discovery. Clin Pharmacol Ther., 2010, 88, 120-125.
79. Wu, C.H.; Lee, C.H.; Ho, Y.S. Nicotinic acetylcholine receptor-based blockade: applications of molecular targets for cancer therapy. Clin Cancer Res., 2011, 17, 3533-3541.
80. Russo, P.; Cardinale, A.; Margaritora, S.; Cesario, A. Nicotinic receptor and tobacco-related cancer. Life Sci., 2012 Jun 15. [Epub ahead of print]
81. Bousquet, J.; Anto, J.M.; Sterk, P.J.; Adcock, I.M.; Chung, K.F.; Roca, J.; Agusti, A.; Brightling, C.; Cambon-Thomsen, A.; Cesario, A.; Abdelhak, S.; Antonarakis, S.E.; Avignon, A.; Ballabio, A.; Baraldi, E.;, Baranov, A.; Bieber, T.; Bockaert, J.; Brahmachari, S.; Brambilla, C.; Bringer, J.; Dauzat, M.; Ernberg, I.; Fabbri, L.; Froguel, P.; Galas, D.; Gojobori, T.; Hunter, P.; Jorgensen, C.; Kauffmann, F.; Kourilsky, P.; Kowalski, M.L.; Lancet, D.; Pen, C.L.; Mallet, J.; Mayosi, B.; Mercier, J.; Metspalu, A.; Nadeau, J.H.; Ninot, G.; Noble, D.; Oztürk, M.; Palkonen, S.; Préfaut, C.; Rabe, K.; Renard, E.; Roberts, R.G.; Samolinski, B.; Schünemann, H.J.; Simon, H.U.; Soares, M.B.; Superti-Furga, G.; Tegner, J.; Verjovski-Almeida, S.; Wellstead, P.; Wolkenhauer, O.; Wouters, E.; Balling, R.; Brookes, A.J.; Charron, D.; Pison, C.; Chen, Z.; Hood, L.; Auffray, C. Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Med., 2011, 3, 43.